Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Haarhaus M, Gilham D, Kulikowski E, Magnusson P, Kalantar-Zadeh K.

Curr Opin Nephrol Hypertens. 2020 Jan;29(1):4-15. doi: 10.1097/MNH.0000000000000570.

PMID:
31725015
2.

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.

Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K.

Atherosclerosis. 2019 Nov;290:59-65. doi: 10.1016/j.atherosclerosis.2019.09.002. Epub 2019 Sep 17.

3.

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.

Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG.

Am Heart J. 2019 Nov;217:72-83. doi: 10.1016/j.ahj.2019.08.001. Epub 2019 Aug 9.

PMID:
31520897
4.

Reply to Piquereau and Perros and to Pullamsetti and de Jesus Perez.

Kurakula K, Boucherat O, Van der Feen DE, Bogaard HJ, Kulikowski E, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1190-1191. doi: 10.1164/rccm.201905-1078LE. No abstract available.

5.

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.

Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, Sarsons CD, Gilham D, Daze E, Wasiak S, Studer D, Rinker KD, Sweeney M, Johansson JO, Wong NCW, Kulikowski E.

Clin Epigenetics. 2019 Jul 12;11(1):102. doi: 10.1186/s13148-019-0696-z.

6.

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.

Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GPL, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):910-920. doi: 10.1164/rccm.201812-2275OC.

PMID:
31042405
7.

Apabetalone downregulates factors and pathways associated with vascular calcification.

Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kalantar-Zadeh K, Kulikowski E.

Atherosclerosis. 2019 Jan;280:75-84. doi: 10.1016/j.atherosclerosis.2018.11.002. Epub 2018 Nov 14.

8.

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

Shishikura D, Kataoka Y, Honda S, Takata K, Kim SW, Andrews J, Psaltis PJ, Sweeney M, Kulikowski E, Johansson J, Wong NCW, Nicholls SJ.

Am J Cardiovasc Drugs. 2019 Feb;19(1):49-57. doi: 10.1007/s40256-018-0298-8.

PMID:
30155718
9.

Benefit of Apabetalone on Plasma Proteins in Renal Disease.

Wasiak S, Tsujikawa LM, Halliday C, Stotz SC, Gilham D, Jahagirdar R, Kalantar-Zadeh K, Robson R, Sweeney M, Johansson JO, Wong NC, Kulikowski E.

Kidney Int Rep. 2017 Dec 8;3(3):711-721. doi: 10.1016/j.ekir.2017.12.001. eCollection 2018 May.

10.

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.

Kulikowski E, Halliday C, Johansson J, Sweeney M, Lebioda K, Wong N, Haarhaus M, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K.

Kidney Blood Press Res. 2018;43(2):449-457. doi: 10.1159/000488257. Epub 2018 Mar 16.

11.

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, Kulikowski E, Wong N, Kim SW, Schwartz GG.

Am J Cardiovasc Drugs. 2018 Apr;18(2):109-115. doi: 10.1007/s40256-017-0250-3.

PMID:
29027131
12.

RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.

Jahagirdar R, Attwell S, Marusic S, Bendele A, Shenoy N, McLure KG, Gilham D, Norek K, Hansen HC, Yu R, Tobin J, Wagner GS, Young PR, Wong NCW, Kulikowski E.

Mol Pharmacol. 2017 Dec;92(6):694-706. doi: 10.1124/mol.117.110379. Epub 2017 Sep 29.

PMID:
28974538
13.

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).

Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, Johansson J, Sweeney M, Wong NC, Kulikowski E.

J Cardiovasc Transl Res. 2017 Aug;10(4):337-347. doi: 10.1007/s12265-017-9755-z. Epub 2017 May 31.

14.

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.

Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Norek K, Patel RG, McLure KG, Young PR, Gordon A, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Data Brief. 2016 Jul 29;8:1280-8. doi: 10.1016/j.dib.2016.07.047. eCollection 2016 Sep.

15.

Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57].

Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Atherosclerosis. 2016 Oct;253:345. doi: 10.1016/j.atherosclerosis.2016.05.012. Epub 2016 May 20. No abstract available.

16.

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC, Gordon A, McLure K, Young P.

Atherosclerosis. 2016 Apr;247:48-57. doi: 10.1016/j.atherosclerosis.2016.01.036. Epub 2016 Jan 22. Erratum in: Atherosclerosis. 2016 Oct;253:345.

17.

Can a hospital serve as a hospice?

Kulikowski ES.

J Gerontol Nurs. 1980 Apr;6(4):203-6. No abstract available.

PMID:
6900652
18.

A study of accidents in a hospital.

Kulikowski ES.

Superv Nurse. 1979 Jul;10(7):44-58. No abstract available.

PMID:
256240

Supplemental Content

Loading ...
Support Center